Paper Details

  1. Home
  2. Paper Details

Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.

Author: BhagatYasmin Rusi, CruzMarilou, De LeonJesse M, FelixCarlos, HellerWarren, HollanderDavid A, JensenHarold, VillanuevaLinda

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

Gatifloxacin 0.5% ophthalmic solution was safe and effective for treatment of acute bacterial conjunctivitis with twice-daily administration for 5 days.
Paper Details　
Original Abstract of the Article :
PURPOSE: To evaluate the efficacy and safety of gatifloxacin 0.5% ophthalmic solution administered twice daily for treatment of acute bacterial conjunctivitis. METHODS: Two identically designed, double-masked, multicenter studies in the United States and India enrolled patients 1 year or older with...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/jop.2014.0040

データ提供：米国国立医学図書館（NLM）

Evaluating the Efficacy and Safety of Gatifloxacin for Pink Eye

The field of ophthalmology is constantly seeking new and effective treatments for common eye conditions like pink eye. This research dives into the world of acute bacterial conjunctivitis, a very common and often pesky eye infection. It uses a robust approach, employing two double-masked, multicenter studies to assess the effectiveness and safety of gatifloxacin 0.5% ophthalmic solution, a medication that combats bacterial infections. The researchers carefully analyzed the data from these studies, revealing that gatifloxacin 0.5% was indeed an effective treatment for pink eye when administered twice daily for 5 days.

Gatifloxacin: A Promising Treatment for Bacterial Conjunctivitis

The results demonstrate that gatifloxacin 0.5% was significantly more effective than the vehicle treatment in clearing conjunctival hyperemia (redness) and discharge. This translates to faster recovery for patients suffering from bacterial conjunctivitis. The researchers also observed a significantly higher microbiological cure rate with gatifloxacin compared to the vehicle treatment, signifying its ability to eliminate the bacteria causing the infection.

Keeping Those Eyes Healthy

Knowing the effectiveness of a medication is one thing, but understanding its safety is crucial. This study confirmed that gatifloxacin 0.5% was well-tolerated by patients, with only a small percentage reporting adverse events. This is reassuring news for patients seeking treatment for bacterial conjunctivitis, as it suggests a low risk of unpleasant side effects.

Dr. Camel's Conclusion

This study is like a refreshing oasis in the arid desert of eye infection research. It provides clear evidence that gatifloxacin 0.5% ophthalmic solution is a safe and effective treatment for bacterial conjunctivitis. It's a solution that's both effective and gentle on the eyes, a win-win for those suffering from this pesky condition.

Date :
  1. Date Completed 2015-08-06
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25244402

DOI: Digital Object Identifier

10.1089/jop.2014.0040

Related Literature

Article Analysis
・Effects of gatifloxacin ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.